China Pharma Holdings (CPHI) Cash from Financing Activities (2010 - 2026)
China Pharma Holdings (CPHI) reported Cash from Financing Activities of -$79325.0 for Q1 2026, down 3.26% on a YoY basis from -$81998.9 in Q1 2025, and down 9.28% quarter-over-quarter from -$72592.0 in Q4 2025.
China Pharma Holdings (CPHI) Cash from Financing Activities (2010 - 2026) Analysis & Trends
China Pharma Holdings has reported Cash from Financing Activities for 16 years, with the latest figure at -$79325.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 3.26% year-over-year to -$79325.0; the trailing twelve-month figure through Mar 2026 stood at -$296532.0 (down 152.46% YoY), and the FY2025 full-year result was -$294027.0, down 770.37% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at -$79325.0, down from -$72592.0 in the prior quarter.
- The five-year high for Cash from Financing Activities was $518237.0 in Q1 2023, with the low at -$850555.0 in Q2 2022.
- Historically, Cash from Financing Activities has averaged -$123764.5 across 5 years, with a median of -$54333.0 in 2024.
- Annual changes were most pronounced in 2024 — Cash from Financing Activities soared 633.62% — and 2025, when it tumbled 1885.97%.
- China Pharma Holdings' Cash from Financing Activities stood at -$672063.0 in 2022, then jumped by 104.52% to $30378.0 in 2023, then sank by 278.86% to -$54333.0 in 2024, then slumped by 33.61% to -$72592.0 in 2025, then dropped by 9.28% to -$79325.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$79325.0 (Q1 2026), -$72592.0 (Q4 2025), and -$122214.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 13.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -840.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -1.48 Bn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | -86.10 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | -65.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 1.47 Bn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -77.88 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -11.62 Mn |
| 10 | China Pharma Holdings | 18.87 Mn | 18.70 Mn | 285,487.00 | -79,325.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -79,325.00 |
| Mar 31, 2026 | -79,325.00 |
| Dec 31, 2025 | -72,592.00 |
| Dec 31, 2025 | -72,592.00 |
| Sep 30, 2025 | -122,214.00 |
| Sep 30, 2025 | -122,214.00 |
| Jun 30, 2025 | -22,401.00 |
| Jun 30, 2025 | -22,401.00 |
| Mar 31, 2025 | -76,820.00 |
| Mar 31, 2025 | -76,820.00 |
| Dec 31, 2024 | -54,333.00 |
| Dec 31, 2024 | -54,333.00 |
| Sep 30, 2024 | 6,843.00 |
| Sep 30, 2024 | 6,843.00 |
| Jun 30, 2024 | 6,852.00 |
| Jun 30, 2024 | 6,852.00 |
| Mar 31, 2024 | 6,856.00 |
| Mar 31, 2024 | 6,856.00 |
| Dec 31, 2023 | 30,378.00 |
| Dec 31, 2023 | 30,378.00 |